Portal de Periódicos da CAPES

Clinical and biological implications of driver mutations in myelodysplastic syndromes

2013; Elsevier BV; Volume: 122; Issue: 22 Linguagem: Inglês

10.1182/blood-2013-08-518886

1528-0020

Elli Papaemmanuil, Moritz Gerstung, Luca Malcovati, Sudhir Tauro, Gunes Gundem, Peter Van Loo, Sung-Soo Yoon, Peter Ellis, David C. Wedge, Andrea Pellagatti, Adam Shlien, Michael J. Groves, Simon Forbes, Keiran Raine, Jon Hinton, Laura Mudie, Stuart McLaren, Claire Hardy, Calli Latimer, Matteo Giovanni Della Porta, Sarah O’Meara, Ilaria Ambaglio, Anna Gallí, Adam P. Butler, Gunilla Walldin, Jon W. Teague, Lynn Quek, Alex Sternberg, Carlo Gambacorti‐Passerini, Nicholas C.P. Cross, Anthony R. Green, Jacqueline Boultwood, Paresh Vyas, Eva Hellström‐Lindberg, David Bowen, Mario Cazzola, Michael R. Stratton, Peter J. Campbell,

Chronic Myeloid Leukemia Treatments

Key Points MDS is characterized by mutations in >40 genes, a complex structure of gene-gene interactions and extensive subclonal diversification. The total number of oncogenic mutations and early detection of subclonal mutations are significant prognostic variables in MDS.